Skip to main content
Journal cover image

Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.

Publication ,  Journal Article
Kang, H-J; Roe, MT
Published in: J Cardiovasc Transl Res
February 2014

The clinical trials that failed to demonstrate significant efficacy may not result in development of new therapy but contribute to better understanding of antithrombotic therapy for ischemic heart disease. Negative trials provide important messages about how to interpret and understand the results of clinical trials and apply these results to clinical practices. Although every aspect of clinical trials may influence the outcomes of trials and interpretation of their results, selection of study subjects, endpoints, and measuring risk/benefit are crucial to success of clinical trial. We will review the recent key negative trials on antithrombotic therapy for ischemic heart disease and discuss about their results and implications. The challenge in the future for the development of antithrombotic therapies is to leverage these "lessons learned" from negative clinical trials to improve the design, conduct, and interpretation of future randomized clinical trials.

Duke Scholars

Published In

J Cardiovasc Transl Res

DOI

EISSN

1937-5395

Publication Date

February 2014

Volume

7

Issue

1

Start / End Page

112 / 125

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Risk Assessment
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Humans
  • Hemorrhage
  • Fibrinolytic Agents
  • Evidence-Based Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kang, H.-J., & Roe, M. T. (2014). Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. J Cardiovasc Transl Res, 7(1), 112–125. https://doi.org/10.1007/s12265-013-9532-6
Kang, Hyun-Jae, and Matthew T. Roe. “Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.J Cardiovasc Transl Res 7, no. 1 (February 2014): 112–25. https://doi.org/10.1007/s12265-013-9532-6.
Kang, Hyun-Jae, and Matthew T. Roe. “Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease.J Cardiovasc Transl Res, vol. 7, no. 1, Feb. 2014, pp. 112–25. Pubmed, doi:10.1007/s12265-013-9532-6.
Journal cover image

Published In

J Cardiovasc Transl Res

DOI

EISSN

1937-5395

Publication Date

February 2014

Volume

7

Issue

1

Start / End Page

112 / 125

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Risk Factors
  • Risk Assessment
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Myocardial Ischemia
  • Humans
  • Hemorrhage
  • Fibrinolytic Agents
  • Evidence-Based Medicine